MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting
Rights
ROCKVILLE, MD, February 4,
2025: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell-based
therapeutics, announces that
pursuant to its block admission facility, since 31 December
2024 it has issued 134,754 of common stock, $0.01 par, of the
Company ("Common Stock") in satisfaction of the exercise of share
options and/or vesting of restricted stock units.
Total voting rights
As at 31 January 2024, the total
issued stock capital of the Company following the recent issue of
the new Common Stock is 105,845,847 shares of Common Stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
For further information, please
contact:
|
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
|
|
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 25 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
scientific, technical and regulatory support, we aim to guide them
on their journey to transform human health. Learn
more at maxcyte.com and
follow us on X and LinkedIn.
